key: cord-0873280-esrzc78s
authors: Duarte, Carlos M.; Ketcheson, David I.; Eguíluz, Víctor M.; Agustí, Susana; Fernández-Gracia, Juan; Jamil, Tahira; Laiolo, Elisa; Gojobori, Takashi; Alam, Intikhab
title: Rapid evolution of SARS-CoV-2 challenges human defenses
date: 2022-04-19
journal: Sci Rep
DOI: 10.1038/s41598-022-10097-z
sha: bd64c6e7803f9a3cb7da8c2377edac70f3b12a8c
doc_id: 873280
cord_uid: esrzc78s

The race between pathogens and their hosts is a major evolutionary driver, where both reshuffle their genomes to overcome and reorganize the defenses for infection, respectively. Evolutionary theory helps formulate predictions on the future evolutionary dynamics of SARS-CoV-2, which can be monitored through unprecedented real-time tracking of SARS-CoV-2 population genomics at the global scale. Here we quantify the accelerating evolution of SARS-CoV-2 by tracking the SARS-CoV-2 mutation globally, with a focus on the Receptor Binding Domain (RBD) of the spike protein determining infection success. We estimate that the > 820 million people that had been infected by October 5, 2021, produced up to 10(21) copies of the virus, with 12 new effective RBD variants appearing, on average, daily. Doubling of the number of RBD variants every 89 days, followed by selection of the most infective variants challenges our defenses and calls for a shift to anticipatory, rather than reactive tactics involving collaborative global sequencing and vaccination.

Virus production and mutation. The number of copies of the virus produced depends on the number of people infected globally along with the number of copies transcribed per infected subject. The verified number of diagnosed COVID-19 infections is known to drastically underestimate real infections, and the ratio between the two varies greatly depending on time and geographic region 6, 7 . Confirmed COVID deaths also underestimate real COVID deaths, but are much more accurate compared to confirmed infections 8, 9 . We therefore adopted a model that combines the reported COVID-19 deaths 6 which is just over 4.8 million worldwide (by October 5, 2021) , with an infection fatality ratio to calculate infections 9 . We improved this model to account for the demographics for each country along with age-specific infection fatality ratios 6 . This model estimates the true number of infections by October 5, 2021 at just over 820 million (Fig. 1a) . This should be taken as a rough approximation since any estimation of true infections, as well as true COVID-caused mortality, is subject to multiple sources of uncertainties including extreme differences in testing capacity and reporting of covid mortality according to the countries. Assuming a total transcription of about 10 12 viral genomes per individual along an infection cycle 10 Reproducing the initial rapid rise in number of detected variants in March 2020 (Fig. 1b) requires a significant level of viral diversity in the initial pool, consistent with recent evidence of a larger-than-reported initial outbreak.

Evolutionary processes lead to genetic diversification along a branching process, with the evolutionary tree for SARS-CoV-2 RBD variants ( Fig. 3a ) characterized by a scaling between cumulative branching length and the 1.5 power of subtree size. The cumulative branching length is related to the mean subtree depth, depth = C/A, thus implying that the mean subtree depth scales as the square root of size (Fig. 3a ). This scaling is characteristic of protein phylogenies, and deviates from fully balanced (i.e., resulting from lack of selection) and fully imbalanced trees 18 . This evolutionary tree structure is consistent with non-random universal inferred patterns of evolution across scales, from the molecular level [e.g. protein families 19 ] to phylogenetic differentiation ranging from micro-evolutionary to macro-evolutionary processes, shaping the diversity of life on the planet 18, 19 . Some RBD variants have rapidly risen to be as represented in the population of sequenced isolates as those identified many months before, with two of the RBD variants exceeding the original variant in number of genotypes sequenced after May 2022 (Figs. 2c and 3a, 4, Video S1). As of Oct 5, 2021, the most represented RBD variants in SARS-CoV-2 genomes are the α and γ variants, with the latter, detected after α, being the most represented, showing a selection for infectivity. These highly successful variants include, specifically, the so-called α variant (B.1.1.7), in which a specific mutated amino acid sequence seems to have appeared independently multiple times (Fig. 3a) . Indeed, the α variant has diversified more and faster than other lineages in the RBD region (Fig. 4) . As a result, the branch containing most of the α variants has diversified greatly leading to heavy branches in the SARS-CoV-2 RBD evolutionary tree, with one of the branches rapidly diversifying between August and October, 2021 (Fig. 3a , Video S1). The β (B.1.351) and γ (P.1 as well as P.2) RBD variants (Fig. 3 ) are also being clearly selected in the SARS-CoV-2 RBD evolutionary tree (Fig. 3 , Video S11), with the γ variant being the most prevalent one by October 5, 2021. A further indication of rapid evolution and selection is the rapid progression of the development of a hierarchical distribution of the abundance of the various RBD variants (Video S1), to conform to a power law consistent with the Yule law ( Fig. 2c-e, Fig. S2 ), a long-standing empirical observation for large groups of organisms 20 , which requires exponential growth in the number of taxa (here RBD variants) in a lineage (here SARS-CoV-2) followed by exponential growth within each variant, as clearly seen in the evolutionary tree retrieved for SARS-CoV-2 RBD variants (Fig. 3a) . 

There has been much discussion on the role of impacts on biodiversity in facilitating the arousal of zoonosis 21 . However, the role of the huge, globally-connected human population, in the massive production of viruses propelling the rapid evolution of SARS-CoV-2 has not been sufficiently acknowledged.

Our analysis provides evidence for extraordinarily rapid evolution and selection of SARS-CoV-2, with the number of unique RBD variants doubling every 89 days, which has clearly reached full speed in the Red Queen race, risking outpacing that of human defenses. The same RBD variant, or identical-sequence variant, may arise independently in different locations, as the evolutionary tree suggests for the amino acid sequence shown by the α variant (Fig. 3a) . However, the SARS-CoV-2 evolutionary process deviates from a random process, with unbalanced branch development providing evidence of strong selection (Fig. 3a,b) , consistent with the dynamics observed for the phylogenesis of protein families 18 . Selection processes remove branches that are not infective while leading to heavy branches of the more infective strains (Fig. 3a) . Indeed, the number of copies of the different RBD variants over time is not random, but are under selective pressure, particularly determined by the infectivity of the new variants emerged, as documented for the so-called α (B.1.1.7), β (B.1.351), and γ (P.1 as well as P.2) RBD variants of SARS-CoV-2 (Video S1, Fig. 4 ). The result of this process is a highly hierarchical dynamic distribution of RBD variants, with a rank-abundance structure conforming to Yule's law 20 , with just 3 variants (the original one, α and γ) containing 85% of the total isolates (Fig. 2c-e) . New, highly infective variants can rapidly recruit to this dominant pool (Video S1). Increased vaccination coverage of efficient vaccines should be able to curve this process by reducing the global production rate of SARS-CoV-2 and, hence, its diversification rate, as the evidence for a change in the relationship between total number of variants and total number of isolates provided here suggests, which deserves deeper and dedicated attention.

High mutation rates of RNA viruses, caused by error-prone RNA-dependent RNA polymerases 22 along with the huge virus production mediated by the huge pool of available human hosts propel the rapid evolution of SARS-CoV-2. The presence of a large number of variants in circulation within the same host population activates an additional mechanism, recombination, for virus diversification. Recombination involves the formation of chimeric molecules from parental genomes of mixed origin 22 , which likely contributes to the rapid diversification of SARS-CoV-2. Provided a doubling time of SARS-CoV-2 RBD variants of 89 days, the number of SARS-CoV-2 RBD variants will continue to expand. This rapid diversification and selection of RBD variants predicts the selection of more infective variants becoming dominant in a highly hierarchical distribution dynamically conforming to Yule's law. This heralds a new phase in the pandemic, beyond October 15, 2021, characterized by accelerating evolutionary rates of the virus, which will impose new challenges as new variants of concern, such as the newly detected omicron (B.1.1.529), add to those already detected. However, virus diversification will be slowed down by reduced viral replication derived from growing immunity acquired by the world population through contact with the circulating virus together with increased coverage of efficient vaccines.

Mutation and, possibly, reassortment propel SARS-CoV-2 to be rapidly evolving, implying that human defense tactics need to be reconsidered if we are to overcome the pandemic well before this declines upon reaching the limitation of available hosts. Evolutionary theory posits that hosts develop evolutionary defenses through recombination under sexual reproduction allowing them to modify their genome to anticipate and prevent pathogen attacks 2,23,24 . This requires selection across generations and catastrophic mortality for SARS-CoV-2 morbidity to be selected against. Our defense mechanisms include protections to avoid contact with the virus, and therapies and vaccines once SARS-CoV-2 enters our bodies. External defenses include social distancing, with strict lockdowns proven across many nations to be the most effective defense mechanism, whatever unpopular, to contain the pandemic, along with wearing protections and emerging uses of nanotechnology for virus detection and interception 25, 26 . This effort must be complemented with the continuous development of a diverse suite of universal immunizations, such as multivalent nanobodies 27 and vaccines, eliciting immune defenses that (Fig. 3a) . We identify the variants of interest designated with Greek letters detected through October 5, 2021. www.nature.com/scientificreports/ vary and can defend us against a wide range of RBD variants, existing and forthcoming, as new variants that overcome immune defenses produced by previously infected or vaccinated people arise, as demonstrated by our long experience in coping with the drift and shift of the influenza virus 28 . Indeed, recent reports indicate that the convalescent sera and BNT162b2 mRNA vaccine may not be as effective against some of the variants 29 . Yet, our data shows, encouragingly a slow-down of the doubling time of the number of the RBD variants detected along with a progressive reduction in the number of variants detected per infected person after July, 2021. A likely explanation for this shift in tendency, 17 months after the pandemic was declared, is the increase in the number of vaccinated people globally, a suggestion that requires a dedicated analysis, as indicated earlier.

Evolutionary ecology theory helps formulate predictions on the future behavior of SARS-CoV-2. On the other hand, the COVID-19 pandemic provides an unprecedented opportunity to test evolutionary ecology theory, which has been largely inferential in nature. This is important as never before had an evolutionary process been tracked in real time and with such wealth of openly available genomic data at a global scale. The SARS-CoV-2 validates a number of evolutionary theories and laws, such as the evolutionary underpinning of the partially imbalanced architecture of phylogenetic trees across evolutionary scales 18, 19 , the diversification process responsible for the long-standing Yule law 20 , and the more targeted framework of the Red Queen theory 2 predicting the evolutionary tactics of pathogens.

The development of the vaccine in record time, a feat rendered possible by unprecedented collaboration, has been celebrated as the start of the end of the pandemic. Rather, it may be the beginning of a new phase, where the continuous development of novel and diverse and universal vaccines 30 represents our main defense against the evolving SAS-CoV-2. A universal coronavirus vaccine would ideally protect against existing and future SARS-CoV-2 variants as well as animal-derived coronaviruses that might cause future zoonotic outbreaks and pandemics 30 . This requires sustained global collaboration, and overcoming the challenges derived from the fact that SARS-CoV-2 primarily infect epithelial cells on mucosal surfaces and have limited contact with the systemic immune system, which reduce responses to systemically administered vaccines 30 . In silico analysis of the effectiveness of current vaccines against plausible RBD variants not yet detected, and the design of new effective vaccines against such variants will enable us to overtake SARS-CoV-2 in the evolutionary race, as a reactive, catch-up tactic, as that played to date, will carry continuous risks. Indeed, in silico analysis of detection 31 , infectivity 32 and vaccine design 33 of existing and future variants, represent a model for the growing use of in silico prediction as a tool to anticipate defenses for the pandemic. Artificial Intelligence may further help analyze the immunogenicity of all the nonsynonymous variations across described and predicted SARS-CoV-2 sequences to generate a blueprint for effective vaccine development 34 , considering that infectivity is the main driving force of SARS-CoV-2 variant selection. However, increased vaccination and collaborative efforts in SARS-CoV-2 sequencing enabling the early detection of new variants of concern 17 remain essential strategies to control the pandemic. 

the Global Initiative on Sharing Avian Influenza Data (GISAID, www. gisaid. org) 35 . As of October 5, 2021, more than 3.85 million SARS-CoV-2 genomes are available from around the world.

Mutations in the genome of SARS-CoV-2 are the basis to define its genomic variants. There are several ways to group mutations in COVID-19 virus. GISAID provides generic clades, and more detailed lineages are provided by Phylogenetic Assignment of Named Global Outbreak LINeages (PAN-GOLIN) tool by Rambaut et al. 36 .

In our effort of a daily updated COVID-19 virus Mutation Tracking system [CovMT, https:// www. cbrc. kaust. edu. sa/ covmt, Alam et al. 5 ], we provide mutation fingerprints (MFs). A mutation fingerprint is defined based on all synonymous and nonsynonymous mutations in an isolate genome. To avoid noise and sequencing errors, a minimum frequency of a mutation from the global population of isolate genomes is kept at 0.001%. We include information about GISAID clades and PANGOLIN lineages for easy exploration of variants. A daily updated table on counts of MFs grouped by sampling dates and location is available at https:// www. cbrc. kaust. edu. sa/ covmt/ data/ Varia nts/ World/ World_ varia nts_ summa ry. zip. RBD variants. The Receptor Binding Domain (RBD) region of Spike protein in SARS-CoV-2 is an important domain region that facilitates the binding of this virus to host cells. Unique RBD variants are defined as those showing exactly the same amino acid sequence for the RBD region of the Spike protein for SARS-CoV-2. We group SARS-CoV-2 genomes into RBD variants by taking the subset of Mutation Fingerprints restricted to the RBD region only and considering only the amino acid mutations. To reduce noise, each individual mutation in the mutation fingerprints is supported with global genome population frequency of at least 0.001%. Taking into account genome sequences in GISAID appear from different sequencing technologies and varying coverages (e.g. long sequence technologies with low coverage) we considered very low frequency mutations as potentially representing noise, since complete information on sequencing coverage is not available with all genomes processed. Mutation Fingerprints of RBD variants as well as all other variants with associated metadata are available at CovMT webpage, https:// www. cbrc. kaust. edu. sa/ covmt/ index. php?p= world-varia nts. www.nature.com/scientificreports/ Mutation modeling. We estimate the number of effective mutations per human infection based on a direct modeling approach using Monte Carlo simulation. New RBD variants are generated based on an assumed mutation rate (chosen to fit the data). The fitness of new variants is taken as a Pareto distribution with scale 10 -6 and shape parameter ¼. The proportional population of two variants is assumed to change at a rate proportional to the ratio of their fitnesses, with a characteristic time of twenty days. Isolates are modeled as random samples from the resulting viral population.

Phylogenetic tree for loose RBD variants. We use the phylogenetic tree provided by nextstrain (https:// nexts train. org/ ncov/ global accessed 05/10/2021), which provides the phylogeny of ~ 3.8 × 10 6 genomes sampled between December 2019 and October 2021. We identified which samples had any mutation in the RBD region and pruned the tree to contain only those. We end up with 3170 different RBD loose variants. We also identified which of these variants belonged to the α (B.1.1.7), β (B.1.351), γ (P.1), δ (B.1.617.2), λ (C.37) and µ (B.1.621) lineages using data provided by COVID-19 virus mutation tracker (https:// www. cbrc. kaust. edu. sa/ covmt/). For the analysis of the depth scaling of the tree branches we followed the procedure described in refs. (green), β (blue), γ (purple) and μ (orange).

Fit to power laws. The fits to power laws in Fig. 2 were performed using maximum likelihood 37 .

Received: 14 July 2021; Accepted: 23 March 2022

Disease and evolution

The Masterpiece of Nature: The Evolution and Genetics of Sexuality

Through the Looking-Glass, and What Alice Found There (Macmillan, 1871)

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

CovMT: An interactive SARS-CoV-2 mutation tracker, with a focus on critical variants

Estimating and forecasting COVID-19 attack rates and mortality

Substantial underestimation of SARS-CoV-2 infection in the United States

Exploring the gap between excess mortality and COVID-19 deaths in 67 countries

Estimating the percentage of a population infected with SARS-CoV-2 using the number of reported deaths: A policy planning tool

The total number and mass of SARS-CoV-2 virions in an infected person

A global database of COVID-19 vaccinations

Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis

Prevention of host-to-host transmission by SARS-CoV-2 vaccines

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617.2) variant in vaccinated and unvaccinated individuals in the UK: A prospective, longitudinal, cohort study

Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Influence of the delta variant and vaccination on the SARS-CoV-2 viral load

Detection of SARS-CoV-2 variants requires urgent global coordination

Scaling properties of protein family phylogenies

Universal scaling in the branching of the tree of life

Some statistics of evolution and geographical distribution in plants and animals, and their significance

Why deforestation and extinctions make pandemics more likely

Why do RNA viruses recombine?

The Red Queen hypothesis and plant/pathogen interactions

The state of affairs in the kingdom of the Red Queen

Prospects of nanomaterials-enabled biosensors for COVID-19 detection

Nanotechnology: An emerging approach to combat COVID-19

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Influenza virus: Dealing with a drifting and shifting pathogen

Convalescent-phase sera and vaccine-elicited antibodies largely maintain neutralizing titer against global SARS-CoV-2 variant spikes

Universal coronavirus vaccines-An urgent need

Deepening of in silico evaluation of SARS-CoV-2 detection RT-qPCR assays in the context of new variants

Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating COVID-19 outbreaks

Combatting future variants of SARS-CoV-2 using an in-silico peptide vaccine approach by targeting the spike protein

Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs

COVID-19 Data Repository

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Power-law distributions in empirical data

This research was funded by King Abdullah University of Science and technology through research made available to the Computational BioScience Research Center, CMD and TG. TG. VME and JFG acknowledge funding from "la Caixa" Foundation under the project code SR20-00386 (COVID-SHINE). JFG was supported by Direcció General de Política Universitària i Recerca from the government of the Balearic Islands through the postdoctoral program Vicenç Mut.

C.M.D. and S.A. conceived the study, I.A. generated and curated the genomic data, D.K., V.M.E., and J.F.-G. conducted the data analyses, C.M.D. wrote the first draft of the paper with input from all coauthors, and all coauthors contributed to improving the paper.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-10097-z.Correspondence and requests for materials should be addressed to C.M.D.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.